Advances in Antibody–Drug Conjugates (ADCs) in Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 77
Special Issue Editor
Interests: targeted drug delivery; nanoparticles; antibody-drug conjugates; controlled release; chemoprevention; immunotherapy; cancer vaccine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antibody–drug conjugates (ADCs) are targeted anticancer therapeutics comprising an antibody conjugated to a cytotoxic payload through a linker. This composition confers ADCs with improved specificity and less potential for side-effects than traditional chemotherapy regimens. Several ADCs have been approved for the treatment of both hematological malignancies and solid tumors, and numerous more are in clinical trials. While the composition of ADCs is straightforward, many factors, including antigen affinity/avidity/specificity, hydrophobicity of the construct, stability of the linker, atypical glycosylation patterns, and the presence of specific amino acid residues in the complementarity-determining region, impact the in vivo disposition and therapeutic efficacy of ADCs. This Special Issue will focus on the drug delivery aspects of ADCs and the relationship between the structural features and in vivo disposition of ADCs.
Prof. Dr. Jayanth Panyam
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody–drug conjugates (ADCs)
- therapeutic efficacy
- drug delivery
- structural features
- disposition
- linker design
- payload optimization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
